Exparel 133 MG/10 ML vial 10ML
Ended Awarded Last action
- Contract number
- SPE2DR26FSHD4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $14,312
Award facts
- Contract value 100% obligated
- $14,311.98 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $14,311.98 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for EXPAREL 133 mg/10 ml vials. The delivery order, issued on January 26, 2026, with an ultimate completion date of February 17, 2026, carries no set-aside designation and was issued without subcontractors. This delivery order operates under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V initiative, a $499.999 billion acquisition strategy designed to support recurring pharmaceutical supply needs across Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group's role as a regional prime vendor contractor positions it as a critical supplier within the federal military medical supply chain. The company's established performance across numerous delivery orders for diverse pharmaceutical products—including specialty surgical items, biologics, vaccines, and routine medications—demonstrates its capability to fulfill specialized requirements of DoD healthcare operations. This particular delivery order for EXPAREL, a specialty surgical anesthetic product, exemplifies the breadth of the company's pharmaceutical portfolio supporting military medical facilities globally through firm fixed-price contracting mechanisms that ensure cost predictability for the federal government.
Quick answers
Who was awarded contract SPE2DR26FSHD4?
SPE2DR26FSHD4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 26, 2026.
How much is contract SPE2DR26FSHD4 worth?
The government has obligated $14,312 on SPE2DR26FSHD4.
Is contract SPE2DR26FSHD4 an order under another contract?
Yes. SPE2DR26FSHD4 is a delivery order under SPE2DR25D9305, an indefinite delivery contract.
Was contract SPE2DR26FSHD4 competed?
The extent of competition for SPE2DR26FSHD4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award